Activity of MDI-301, a novel synthetic retinoid, in xenografts
| Autor: | Neil M. Kernohan, Mary O’Neill, Susan E. Bray, Jian Zhang, Virginia Appleyard, Karen Murray, Alastair M. Thompson, George Thomson, James Varani |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Receptors Retinoic Acid Mice Nude Alpha (ethology) Antineoplastic Agents Breast Neoplasms Tretinoin Mice Retinoids Prostate cancer Breast cancer In vivo Cell Line Tumor Internal medicine Animals Humans Medicine Pharmacology (medical) skin and connective tissue diseases Receptor Alitretinoin Pharmacology business.industry Retinoic Acid Receptor alpha Prostatic Neoplasms medicine.disease Immunohistochemistry Xenograft Model Antitumor Assays In vitro Cancer cell Toxicity Cancer research Female business |
| Zdroj: | Anti-Cancer Drugs. 15:991-996 |
| ISSN: | 0959-4973 |
| Popis: | The efficacy of MDI-301, a non-toxic novel synthetic retinoid, was found to be equivalent to the natural 9-cis-retinoic acid (RA) in vitro against estrogen-dependent MCF7 and T47D breast cancer cell lines which express RA receptor (RAR) alpha. Both retinoids also showed similar efficacy against established PC-3 prostate carcinoma xenografts. MCF7 tumor xenografts showed a reduction in tumor growth of 48% without systemic side-effects upon treatment with MDI-301 compared with MCF7 controls. Tumor xenografts derived from MDA-MB-231, an estrogen-independent breast cancer cell line that expresses low levels of RARalpha, were unresponsive. This study demonstrates that MDI-301 is as efficacious as 9-cis-RA against cancer cells with RARalpha, with no signs of toxicity in vivo, making it a potential candidate for cancer therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|